All peptides
Growth hormoneModerate

CJC-1295

Modified GRF 1-29 · DAC:GRF

A growth-hormone-releasing hormone analogue that raises the baseline of natural GH output rather than replacing it.

How it works

Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week.

Structure: 30 amino acid GHRH analogue

Reported benefits

  • Elevated GH and IGF-1 across the dosing window
  • Improved sleep depth reported by most users
  • Supports lean mass retention and fat oxidation

Practical considerations

  • Usually paired with a GHRP such as Ipamorelin for a synergistic pulse
  • No-DAC (Mod GRF 1-29) suits pulsatile dosing; DAC suits steady elevation
  • GH elevation is not desirable for everyone — screen for cancer history

Side effects and risks

  • Water retention
  • Tingling or numbness in hands
  • Head rush and flushing after injection
  • Elevated fasting glucose at higher doses

Dosing overview

100 mcg (no-DAC) 1–3× daily, or 1–2 mg weekly for the DAC version

This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.

Research references

  • Teichman et al., 2006 — CJC-1295 pharmacokinetics in healthy adults